GRI Bio, Inc. (GRI)
1.93
+0.09
(+4.89%)
USD |
NASDAQ |
Sep 18, 16:00
1.90
-0.03
(-1.55%)
After-Hours: 20:00
GRI Bio Shareholders Equity (Quarterly) : 10.28M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.28M |
| March 31, 2026 | 10.54M |
| December 31, 2025 | 6.008M |
| September 30, 2025 | 1.993M |
| June 30, 2025 | 3.322M |
| March 31, 2025 | 1.205M |
| December 31, 2024 | 4.032M |
| September 30, 2024 | 3.66M |
| June 30, 2024 | 4.719M |
| March 31, 2024 | 2.798M |
| December 31, 2023 | 0.259M |
| September 30, 2023 | 2.227M |
| June 30, 2023 | 4.038M |
| March 31, 2023 | 0.031M |
| Date | Value |
|---|---|
| December 31, 2022 | -1.625M |
| September 30, 2022 | 3.459M |
| June 30, 2022 | 3.666M |
| March 31, 2022 | 3.36M |
| December 31, 2021 | 5.818M |
| September 30, 2021 | 8.729M |
| June 30, 2021 | 9.853M |
| March 31, 2021 | 12.03M |
| December 31, 2020 | -1.454M |
| September 30, 2020 | -0.024M |
| June 30, 2020 | 0.969M |
| March 31, 2020 | |
| December 31, 2019 | 3.214M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 11.38M |
| Total Liabilities (Quarterly) | 1.10M |
| Debt to Equity Ratio | 0.0043 |
| Current Ratio | 10.30 |
| Net Debt Paydown Yield | 0.33% |